IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HOLMBERG et al

Application No.: PCT/SE2004/001549 Art Unit: not yet assigned

Filed: October 25, 2004 Examiner: not yet assigned

Title: A NOVEL MUTATED NERVE GROWTH FACTOR BETA GENE,

PROTEINS ENCODED THEREBY, AND PRODUCTS AND

METHODS RELATED THERETO

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. §1.98, a copy of each of the documents cited is enclosed.

All the documents enclosed are in English. The filing of this Information Disclosure Statement shall not be construed as a representation that a prior art search has been made. Additionally, the filing of this Information Disclosure Statement shall not be construed to be an admission that each of the references submitted herewith is in fact prior art with respect to the present application, or that each of the references is considered to be material to patentability as defined in 37 C.F.R. §1.56(b).

The documents are being submitted within three months of the filing date or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. §1.97(b).

Patent Attorney Docket No. 73247-83506

To assist the Examiner, the documents are listed on the attached forms <u>PTO/SB/04A and B</u>. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully Submitted,

O'le

April 21, 2006

Olivia Tolan, Reg. No. 45,161

ALBIHNS STOCKHOLM AB Box 5581 SE-114 85 Stockholm, Sweden tel +46 (0) 8 5988 7200 fax +46 (0) 8 5988 7300 Customer No. 26288